Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
THTX(NASDAQ:THTX) MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that the Company has obtained the final order from the Superior Court of Québec (Commercial Division) approving the previously-announced plan of arrangement (the “Arrangement”) under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”). This final court approval follows the approval of the Arrangement by the shareholders of the Company at the special meeting of shareholders held on September 12, 2025.
Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak
THTX(NASDAQ:THTX) MONTREAL, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that two leading independent proxy advisory firms, Institutional Shareholders Services Inc. (“ISS”) and Glass Lewis & Co. LLC (“Glass Lewis”), have each recommended that the shareholders of the Company (the “Shareholders”) vote “FOR” the special resolution (the “Arrangement Resolution”) to approve the plan of arrangement (the “Arrangement”) involving the Company and CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”), a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products.
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
THTXMONTREAL, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) announced today that it has filed and is in the process of mailing the management proxy circular (the “Circular”) and related materials in connection with its special meeting (the “Meeting”) of shareholders of the Company (the “Shareholders”) to be held in a hybrid format on Friday, September 12, 2025 at 10:00 a.m. (Eastern time) in connection with its previously announced transaction to be acquired by CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”), a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products.
Theratechnologies Unveils Novel Data At ACTHIV 2025 Underscoring Importance Of Managing Excess Visceral Abdominal Fat (EVAF) in People With HIV
THTXTheratechnologies Provides Update on Sale Process; Says The Board Of Directors Of The Company Has Decided To Further Evaluate The Potential Sale Of The Company Through An Open And Non-Exclusive Process
THTXReported Saturday, Soleus Capital Sends Letter To Theratechnologies Board, Presses For Immediate Engagement With Future Pak
THTXReported Friday, Theratechnologies Rejects Future Pak's Proposals, Cites Ongoing Exclusive Negotiations With Alternate Buyer
THTXWhat's Going On With Theratechnologies Shares Friday?
THTXTheratechnologies shares are moving higher on Friday following Future Pak's proposal to acquire the company for $255 million.
Future Pak Submits Proposals to Buy Theratechnologies, Offering up to $255M in Total Value
THTXTheratechnologies Q1 2025 GAAP EPS $0.00 Misses $0.01 Estimate, Sales $19.05M Miss $19.62M Estimate
THTXExamining the Future: Theratechnologies's Earnings Outlook
THTXThe FDA Approved Theratechnologies' Prior Approval Supplement To The Supplemental Biologics License Application For Egrifta SV (Tesamorelin For Injection). Tesamorelin For Injection Is Approved In The Us To Reduce Excess Abdominal Fat In Adults With HIV A
THTXTheratechnologies Says FDA Approved Supplemental Biologics License Application For F8 Formulation Of Tesamorelin For Injection
THTXTheratechnologies Presented Data From A Real-world, Observational, Registry Study Demonstrating The Efficacy And Safety Of Ibalizumab In Reducing HIV RNA To Undetectable Levels In Heavily Treatment-experienced Patients With Multidrug Resistant HIV
THTXTheratechnologies Q4 2024 GAAP EPS $(0.16) May Not Be Comparable To $0.05 Estimate, Sales $25.00M Beat $22.69M Estimate
THTXReported Earlier, Theratechnologies Resumes Distribution Of EGRIFTA SV As FDA Clears Two Newly Manufactured Batches
THTXReported Earlier, Theratechnologies Alerts Patients to EGRIFTA SV Supply Shortage Amid Manufacturing Shutdown
THTX